Vertex & Canada Pricing Alliance Back-and-Forth on CF Drug Reimbursement

Country: CANADA-ONTARIO | Region: NORTH AMERICA | Type: Pricing & Reimbursement | Keywords: #canadiancftreatmentsociety #cysticfibrosis #pancanadianpricingalliance #portfoliodeal #vertex

PRICENTRIC BRIEF:

  • Although Vertex’s three cystic fibrosis (CF) drugs Kalydeco (ivacaftor), Orkambi (lumacaftor/ivacaftor), and Symdeko (tezacaftor/ivacaftor and ivacaftor) are approved for use in Canada, the drugmaker and the pan-Canadian Pricing Alliance have yet to agree on reimbursement rates
  • Vertex has reportedly made five different offers to Canada’s pricing alliance for reimbursement rates over the past few years to seemingly no avail—at the same time, the drugmaker has expressed its willingness to continue talks with government officials to ensure patient access to their profile of CF medicines
  • Vertex has agreed to the Canadian CF Treatment Society’s 100 day challenge with the Ontario Minister of Health, Christine Elliott, to negotiate and conclude a portfolio deal for Vertex’s medicines, including Trikafta (elexacaftor/ivacaftor/tezacaftor), within 100 days

THE DETAILS

OTTAWA, Canada – Although Vertex’s three cystic fibrosis (CF) drugs Kalydeco (ivacaftor), Orkambi (lumacaftor/ivacaftor), and Symdeko (tezacaftor/ivacaftor and ivacaftor) are approved for use in Canada, the drugmaker and the pan-Canadian Pricing Alliance have yet to agree on reimbursement rates.

Vertex has reportedly made five different offers to Canada’s pricing alliance for reimbursement rates over the past few years to seemingly no avail. At the same time, drugmaker has expressed its willingness to continue talks with government officials to ensure patient access to their profile of CF medicines.

Vertex has agreed with the Canadian CF Treatment Society’s 100 day challenge with the Ontario Minister of Health, Christine Elliott, to negotiate and conclude a portfolio deal for Vertex’s medicines, including Trikafta (elexacaftor/ivacaftor/tezacaftor), within 100 days.

In a press release from the Canadian CF Treatment Society, Duncan McKechnie, Vertex Executive, “To date we have made five offers to the pan-Canadian pricing alliance, including a portfolio offer. In the 18 months I have been in my role we have yet to receive any meaningful indication that the Ontario or Canadian governments wish to engage with Vertex.”

 

Learn more about Pricentric One and our Global Pricing Solutions!

Contact us with your questions and global pricing needs, and an expert will follow up shortly.